New obesity drug combo aims for greater weight loss

NCT ID NCT07463846

Recruiting now Disease control Sponsor: Alnylam Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 13, 2026 · Updated 5 times

Summary

This study tests an experimental drug called ALN-2232, given alone or together with the approved weight-loss drug tirzepatide, in 156 adults with obesity. The goal is to see if the combination is safe and leads to more weight loss than either drug alone. Participants will receive injections and be monitored for side effects and changes in body weight.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ALN-2232 (an experimental drug) and tirzepatide (a weight-loss drug)
What this could lead to: If successful, this could lead to a new combination treatment for obesity that helps people lose more weight than current options.
What could go wrong: This is an early-phase trial with only 156 participants, so results may not apply to everyone. The experimental drug ALN-2232 has unknown safety and effectiveness at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

Clinical Trial Site
RECRUITING

Mount Royal, H3P 3P1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.